![image: [ A new generation of drugs spells hope for MS sufferers ]](/olmedia/90000/images/_90541_drugs_300.jpg)
The drug interferon beta-1a is the latest in a new generation of treatments for patients who suffer chronic relapses of multiple sclerosis (MS).
The new drugs, which first appeared two years ago, can reduce the symptoms and slow progression of the illness.
Interferon beta-1a, which is produced by the Swiss company Ares-Serono is already sold in Canada.
It is awaiting licensing approval in the United States and is due to be launched in five other countries this month.
Trials have shown the drug:
Self-administered by an under-the-skin injection, it is also said to double the chances of patients being free of relapses altogether.
The cost of relief
About 100,000 people in Britain suffer from MS, a disease of the central nervous system which causes numbness, pins and needles, tremors and paralysis.
While no cure exists, one form of MS characterised by interspersed remissions and relapses is treatable with the new generation drugs like interferon beta-1a.
However, at ú9,500 a year per patient, MS experts fear many of the 8,000 sufferers who could benefit from the drug will be denied it because of the cost.
Only about a tenth of that number are said to be now receiving one of the two other drugs currently available.
Peter Cardy, the chief executive of the Multiple Sclerosis Society blames the fact that treatment for people with MS varies greatly.
"While some heath authorities make the new drugs available to all who are prescribed them, some refuse to fund them at all," Mr Cardy said.
"The situation is unfair and unacceptable. We want to see the government enforce equitable guidelines and take firm action against healthcare purchasers who fail to observe them."
Richard Hughes, a professor of neurology at Guy's Hospital in London, believes the effectiveness of interferon beta-1a strengthens the case for more spending on MS treatment.
As one of the leading scientists involved in the trials, he claims interferon beta-1a represents a breakthrough in the treatment of MS.
"The trials show conclusive evidence of benefit. I think it should persuade the health authorities to make the drug available for patients with this type of MS," Mr Hughes said.
Cannabis campaign on the move
(29 Mar 98á|áUK)
Jail warning for 'medicinal' cannabis user
(14 Mar 98á|áUK)
NHS treatment dependent on location, survey says
(16 Dec 97á|áUK)
Disabled 'use cannabis with doctors' support'
(26 Oct 97á|áSci/Tech)
Multiple Sclerosis Information
The Multiple Sclerosis Society
British Medical Association
The BBC is not responsible for the content of external internet sites.
Microsoft clears major hurdle
(From Business)
Pill can 'boost or kill' sex drive
Breast cancer drug trials 'must go on'
BT plans millions for Net demand
(From Business)
New antibiotics to beat the bugs
The simplest element can withstand titanic pressures
Legal action threatened over millenium bug
Getting close to Europa
Genetic patents given go-ahead
Power cut at nuclear plant
German test case for net censorship
Helping the kneedy
Make the most or you're toast
Online Yeltsin vows action on India
</x-html>